Despite winning its first trial in November 2017, Testim gel makers, Auxilium, settled a lawsuit for an undisclosed amount, just days before the trial in Pennsylvania’s Philadelphia Court of Common Pleas. Allegations put forth by the plaintiff who suffered a stroke (induced by Testim gel use) included marketing an unreasonably dangerous product and misleading the consumers by false marketing gimmicks which characterized low testosterone levels normally experienced by aging men as an “epidemic” and a “syndrome” called “Low-T”.
Over 6,000 testosterone replacement therapy (TRT) lawsuits have been centralized under MDL No. 2545 in the U.S. District Court for the Northern District of Illinois before U.S. District Judge Matthew Kennelly. Three bellwethers convened last year resulted in two wins for the plaintiffs totaling about $290 million to be paid by AndroGel maker AbbVie and one win for Auxilium.